Good MorningInvestors continue to bet on growth despite the rising specter of inflation. The S&P 500 reversed early losses on Wednesday to close with a small gain going into the holiday weekend. The move is the 15th day of trading within a near-term consolidation range that is fast becoming a bullish-looking flag pattern. If the market breaks out to the upside and confirms this pattern within the next week or so it should rally well into the end of the year.
In economic news, the PCE Price Index was released on Wednesday coming in largely as expected. The rub is that “as expected” included a 0.20% month-to-month increase and the fastest pace of YOY gains for several decades. At this pace, the market should expect the first interest rate hikes to come well before the middle of next year.
Featured: Could this be crypto's biggest Trump win? (Ad) 
|
Stocks | | | Despite attention on green energy, oil-and-gas stocks such as EOG Resources (NYSE: EOG), Callon Petroleum (NYSE: CPE) and Matador Resources (NYSE: MTDR) all traded higher this week, and all found support at a key moving average. Read the Full Story |
|
From Our PartnersWith the next presidential cycle heating up and Trump leading the charge, major market shifts are already taking shape.
For investors who position early, the opportunities could be significant.
That’s why we’ve just released a brand-new report:
📈 “5 Best Stocks to Buy Under Trump’s Presidency.” | | | Get the full report here—and stay ahead of the curve. |
|
Markets | | | This year has been a busy year for IPO’s. If there is one thing we’ve learned it’s that rushing in to buy an IPO on the first day, or even within the first few days, isn’t always the smartest thing to do, even when the underlying company is fundamentally sound. Three of the latest IPO’s are no different. Read the Full Story |
|
Politics | | | The holiday tree is towering over the main square in this central German city, the chestnuts and sugared almonds are roasted, and kids are clambering aboard the merry-go-round just like they did before the pandemic. But a surge in coronavirus infections has left an uneasy feeling hanging over Frankf... Read the Full Story |
|
|
Politics | | | Global stock markets mostly rose Thursday after Federal Reserve officials indicated they were ready to hike interest rates sooner than expected if needed to cool U.S. inflation.
London, Tokyo, Frankfurt and Hong Kong markets advanced, while Shanghai declined.
Wall Stree... Read the Full Story |
|
Markets | | | With November shaping up to be yet another record setting month for U.S. stocks, it’s time to look ahead at what December may bring. While predicting near term market movements is difficult, like last year, there’s a good chance this month’s run turns into a Santa Claus rally. As h... Read the Full Story |
|
|
Markets | | | Homebuilders and other real estate companies are increasingly betting that would-be homebuyers frustrated with a shortage of homes for sale and runaway prices will settle for renting their slice of the American Dream Read the Full Story |
|
Politics | | | A fire at a coal mine in Russia's Siberia killed 11 people and injured more than 40 on Thursday, with dozens of others remaining trapped, authorities said.
Efforts to rescue those trapped in the mine were halted on Thursday afternoon because of an explosion threat, and rescuers were r... Read the Full Story |
|
Politics | | | For 26 years, Ernest Ray worked at a company in southwest Virginia that made compressors, in a physically demanding job that involved night shifts on a factory floor. When the plant closed in 2018, Ray applied for and received about $9,000 in unemployment benefits.
Three years later, ... Read the Full Story |
|
Stocks | | | Now the holiday feasting is over it’s time to get back to business. With the New Year just around the corner, the business at hand is preparing for the coming year. The outlook for earnings growth is tepid and marred by inflation but not all companies are in the same positions. Read the Full Story |
|
Markets | | |
Suspect that you might need a financial advisor or financial planner? Deciding whether to add a financial advisor to your "team" might depend on a variety of reasons, both personal and practical. The end of the year might be the right time to search for your newest team member.
In a CNBC and Acor... Read the Full Story |
|
The Early Bird Stock Of The Day Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. | | View Today's Stock Pick |
|
